Silexion Therapeutics is implementing a 1-for-24 reverse share split effective November 11, 2026, to regain compliance with Nasdaq's minimum bid price requirement. This move aims to strengthen the company's market position and support its ongoing Phase 2/3 clinical trial of SIL204 for pancreatic cancer. Shareholders will see their shares consolidated automatically, with no action required. The split is expected to reduce stock volatility, broaden investor interest, and improve funding flexibility for advancing cancer treatment development.
Silexion Therapeutics' reverse share split is noted here with Pluang's Health sector market data as of Nov 09, 2026 18:41 WIB. For readers following Health-sector stocks, 108 of 150 priced US stocks rose while 26 fell today. Notable movers include FLNA at USD 0.48 with a +6.01% change and a typical hold time of 39 days, LFST at USD 12.99 down -5.66%, and IONS at USD 37.25 down -5.50%.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
